Joern Kekow

Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept

Dirk Koczan, Susanne Drynda, Michael Hecker et al. · Arthritis Research & Therapy · 2008 · 119 citations · Full text

Life Sciences, Immunology, Molecular Medicine +17

Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Claudia Kedor, Joachim Listing, Jan Zernicke et al. · Annals of the Rheumatic Diseases · 2020 · 99 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register

Imke Redeker, Katinka Albrecht, Joern Kekow et al. · Annals of the Rheumatic Diseases · 2021 · 92 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity

Holger Kudela, Susanne Drynda, Anke Lux et al. · BMC Rheumatology · 2019 · 68 citations · Full text

Life Sciences, Immunology, Pediatrics +16

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register

Martin Schäfer, Katinka Albrecht, Joern Kekow et al. · RMD Open · 2023 · 57 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17